Average Co-Inventor Count = 7.88
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (10 from 3,681 patents)
2. Janssen Biotech, Inc. (9 from 410 patents)
3. Janssen Pharmaceutica Nv (4 from 2,076 patents)
4. Other (1 from 832,680 patents)
5. National Institutes of Health, a Component of the US Dept. of Health & Human Services (1 from 3,435 patents)
24 patents:
1. 12304939 - EGFR and C-met fibronectin type III domain binding molecules
2. 12077592 - GPRC5D chimeric antigen receptors and cells expressing the same
3. 12018289 - Vaccines based on mutant CALR and JAK2 and their uses
4. 11884722 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
5. 11685777 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
6. 10954284 - EGFR and c-Met fibronectin type III domain binding molecules
7. 10774130 - Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
8. 10662235 - Cysteine engineered fibronectin type III domain binding molecules
9. 10562968 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
10. 10106620 - Blocking CD38 using anti-CD38 F(ab')2 to protect NK cells
11. 10072088 - Anti-BCMA antibodies and uses thereof
12. 9902762 - Multivalent fibronectin based scaffold domain proteins
13. 9850310 - CD123 binding agents and uses thereof
14. 9725497 - EGFR and C-Met fibronectin type III domain binding molecules
15. 9695228 - EGFR and c-Met fibronectin type III domain binding molecules